08:18High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
10:12Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
10:11Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
06:04Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
11:07Macrophage Cholesterol Depletion and Its Effect on the Phagocytosis of Cryptococcus neoformans
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay
Published on: January 7, 2019
Alessia Di Costanzo1, Ilaria Pirona2, Silvia Buonaiuto3
1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Lifelong inactivation of the APOB gene significantly lowers cardiovascular risk but elevates chronic liver disease (CLD) risk, particularly in individuals with obesity and diabetes. This highlights a critical balance between cardiovascular protection and liver health.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: